Exelixis gains as catalyst calendar and buyback support drive renewed demand
Exelixis shares rose after investors refocused on the company’s 2026 pipeline catalysts and ongoing capital returns, following recent reaffirmation of milestone-rich mid-2026 trial readouts and continued buyback capacity. The move appears flow-driven rather than tied to a single new press release, with the stock trading near the $45 level highlighted in prior analyst target resets.
1) What’s moving the stock
Exelixis (EXEL) traded higher in today’s session, with the day’s move looking driven by renewed positioning into the company’s 2026 event calendar rather than a single headline. Recent company communications have emphasized multiple mid-2026 clinical catalysts for zanzalintinib across pivotal studies, alongside continued execution of its cabozantinib franchise and shareholder returns, which can support incremental demand on quieter news days. (ir.exelixis.com)
2) The fundamental backdrop investors are re-pricing
The company recently reported fourth-quarter and full-year 2025 results and outlined 2026 priorities, including anticipated mid-2026 readouts for key STELLAR trials and additional planned trial initiations. Separately, Exelixis has an ongoing FDA review for a zanzalintinib-based colorectal cancer filing with a target action date in December 2026, giving investors a longer-dated regulatory anchor in addition to nearer-term data catalysts. (ir.exelixis.com)
3) Why the move can happen without a fresh headline
With the stock trading around the mid-$40s, investor flows can be influenced by proximity to widely discussed valuation levels and target prices, especially when the company’s own updates keep attention on upcoming catalysts and when buyback authorizations are in place through late 2026. In that context, a modest 3% move can reflect positioning, technical buying, and sector tape rather than a discrete company announcement. (ir.exelixis.com)
4) What to watch next
Near-term, investors will monitor the next earnings date and any incremental updates on cabozantinib demand trends, commercialization execution, and progress toward the mid-2026 trial readouts the company has guided to. The next major step-change catalysts remain pivotal trial data updates for zanzalintinib programs and any regulatory communications tied to the colorectal cancer filing timeline. (investing.com)